Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Investment Securities (2016 - 2025)

Regenxbio (RGNX) has 12 years of Gains from Investment Securities data on record, last reported at $551000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 163.55% year-over-year to $551000.0; the TTM value through Dec 2025 reached $613000.0, up 175.96%, while the annual FY2025 figure was $613000.0, 93.87% down from the prior year.
  • Gains from Investment Securities reached $551000.0 in Q4 2025 per RGNX's latest filing, up from $74000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.9 million in Q4 2022 and bottomed at -$4.1 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $515450.0, with a median of $58500.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 5275.68% in 2021, then plummeted 665.24% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$4.1 million in 2021, then soared by 339.99% to $9.9 million in 2022, then crashed by 138.37% to -$3.8 million in 2023, then surged by 77.15% to -$867000.0 in 2024, then surged by 163.55% to $551000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $551000.0 in Q4 2025, $74000.0 in Q3 2025, and $1.0 million in Q2 2025.